Lost money at your DexCom, Inc.

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the company’s officers.

If you have invested in DexCom, we recommend you visit for more information .

Investors have until October 21, 2024 to request the court to appoint them to lead the case. The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in DexCom securities. The case is pending in the U.S. District Court for the Southern District of California and is captioned Alonzo v. DexCom, Inc.No. 24-cv-01485.

What is the lawsuit about?

DexCom develops glucose monitoring systems for diabetes management. The company discussed its ability to leverage its growth potential to achieve projected record new patient numbers while exceeding the previous fiscal year’s gross margins while increasing customer conversion to the new G7 platform.

After the market closed on July 25, 2024, DexCom announced disappointing second-quarter 2024 earnings results and lowered full-year revenue guidance to between $4 billion and $4.05 billion from $4.35 billion. The news caused DexCom shares to fall sharply. The Company’s stock price closed at $107.85 per share on July 25, 2024. Prior to the market open on July 26, 2024, DexCom stock was trading in the range of $66.60 per share, down $41.25 per share, or 38%. .

Click here for more information: .

What can you do?

If you have invested in DexCom, Inc., you may have legal options and may be required to provide your information to the company. All representations are made on a contingency fee basis and there are no costs to you. The shareholders are not responsible for any court costs or litigation costs. The Company will seek court approval for any fees and expenses.

Submit your information by visiting:

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder lawsuits. It was named one of the top five plaintiff law firms by ISS SCAS in 2023 and its attorneys were named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Recent notable successes include BFA being valued at over $900 million by the board of Tesla, Inc. (pending court approval) and $420 million by Teva Pharmaceutical Ind. Ltd. has requested back.

For more information about BFA and its attorneys, see

Lawyer advertising. Past results are no guarantee of future results.